Last reviewed · How we verify

Xolair injections — Competitive Intelligence Brief

Xolair injections (Xolair injections) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-IgE monoclonal antibody. Area: Immunology / Allergy.

marketed Anti-IgE monoclonal antibody Immunoglobulin E (IgE) Immunology / Allergy Small molecule Live · refreshed every 30 min

Target snapshot

Xolair injections (Xolair injections) — University of California, Los Angeles. Xolair is a monoclonal antibody that binds to circulating immunoglobulin E (IgE), preventing it from interacting with high-affinity IgE receptors on mast cells and basophils.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Xolair injections TARGET Xolair injections University of California, Los Angeles marketed Anti-IgE monoclonal antibody Immunoglobulin E (IgE)
ANTI-IGE THERAPY (XOLAIR) ANTI-IGE THERAPY (XOLAIR) Children's Hospital of The King's Daughters marketed Anti-IgE monoclonal antibody Immunoglobulin E (IgE)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-IgE monoclonal antibody class)

  1. Children's Hospital of The King's Daughters · 1 drug in this class
  2. University of California, Los Angeles · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Xolair injections — Competitive Intelligence Brief. https://druglandscape.com/ci/xolair-injections. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: